Deterioration is understood as an absolute decline in predicted FVC of ≥ 10% in the last 12 months.Where there is an absolute decline in predicted FVC of ≥10% over a 12-month period, treatment must cease.Some of you may recall that several months ago CPFF conducted a survey to be able to provide patient insight to the Common Drug Review (CDR) Process for OFEV® (nintedanib).

Prioritizing patient support by providing important access and financial resource solutions. May expedite the time spent creating an OFEV prescription

OFEV is an FDA-approved medicine that helps slow lung function decline in patients with IPF. The HeadStart™ Patient Assistance Program offers patients access to a team of experts working together to help guide and support patients during the treatment process and includes services such as information about IPF, access to regional resources and support groups, help with reimbursement, medication delivery, and information about Ofev®. If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.Combination use of pirfenidone and nintedanib will not be funded.Patients who have experienced intolerance or failure to pirfenidone or nintedanib will be considered for the alternate agent provided that the patient continues to meet the above coverage criteria.All requests for nintedanib must be completed using the Nintedanib/Pirfenidone Special Authorization Request Form (ABC 60051).Adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF):Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥10% from initiation of therapy until renewal (initial six month treatment period).

PhD, Director, Division of Respirology at McMaster University.

This site is intended for US healthcare professionals only.Complete and submit the electronic form with your patients. Notes: Patients who have experienced intolerance or failure to Ofev (nintedanib) or Esbriet (pirfenidone) will be considered for the alternate agent provided that the patient continues to meet the above coverage criteria.Adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF):for treatment of idiopathic pulmonary fibrosis, in persons:The initial authorization and requests for continuation of treatment will be authorized for a maximum duration of 12 months.Upon subsequent requests, the physician must provide proof of a beneficial clinical effect defined by the absence of deterioration in the patient’s condition. As the impact of nintedanib on the effectiveness of hormonal contraception is unknown, advise women using hormonal contraceptives to add a barrier method. Box 5070, Louisville, KY 40205-0070. If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.Combination use of Ofev (nintedanib) and Esbriet (pirfenidone) will not be funded.For the treatment of mild to moderate idiopathic pulmonary fibrosis in adult patients confirmed by a respirologist and a high-resolution CT scan within the previous 24 months.All other causes of restrictive lung disease should be excluded. 5. In 2 out of 3 medical studies, OFEV significantly reduced the risk of a first acute exacerbation. Start a PA. Initiate a new PA online now or call 1-866-452-5017 to speak with a Case Manager. The Boehringer lngelheim Cares Foundation (Bl Cares) is a non-profit organization with a mission to improve patient lives and strengthen our communities. The program requires a completed application form signed by patient …